No Summary

Tempus to buy cancer test maker Personalis for $1.5 billion - Reuters

Tempus to buy cancer test maker Personalis for $1.5 billion

Sources

• Reuters
  Tempus to buy cancer test maker Personalis for $1.5 billion
• Barron's
  Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
• Business Wire
  Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
• Bloomberg.com
  Tempus AI to Buy Cancer-Tech Firm Personalis For $1.7 Billion
• Fierce Biotech
  Tempus buys out cancer genomics partner Personalis in $1.5 billion deal